Disease-modifying therapies in amyotrophic lateral sclerosis

Area of Science:

• Neuroscience
• Neurology
• Genetics

Background:

• Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting motor neurons.
• Cognitive impairment occurs in approximately 50% of ALS cases.
• TDP43 protein aggregation is a key pathological hallmark in nearly all ALS patients.

Purpose of the Study:

• To review pathological mechanisms underlying ALS.
• To present current and future therapeutic strategies for ALS.
• To discuss challenges in ALS clinical trial design and disease heterogeneity.

Main Methods:

• Literature review of pathological mechanisms in ALS.
• Analysis of current pharmacological treatments (riluzole, edaravone).
• Exploration of emerging therapies including gene and stem cell treatments.

Main Results:

• Riluzole and edaravone provide only modest benefits in ALS progression.
• Significant obstacles exist in developing effective ALS therapies, including trial design and disease heterogeneity.
• TDP43 proteinopathy is a near-universal pathological feature.

Conclusions:

• There is a critical need for novel disease-modifying therapies for ALS.
• Future research should focus on addressing pathological mechanisms and improving clinical trial methodologies.
• Gene and stem cell therapies represent promising avenues for ALS treatment.